Immunovant Sector: Pharmaceuticals and biotechnology (autoimmune and immunology therapeutics) HQ: 320 W 37th St., New York, NY Year Founded: 2018 Key Leaders: Eric Venker, MD, PharmD, CEO Number of Employees: 362 Stage: Public Financial Snapshot: $3.83 billion Notable Investors: SG Americas Securities, Roivant Sciences, RTW Investments, and BVF Partners Key Products: Immunovant is developing Batoclimab, an FcRn-targeting monoclonal antibody for autoimmune diseases (MG, TED, Graves disease), which is in Phase 3 registrational trials
BPC 157 offers numerous clinical benefits for individuals recovering from injuries: Speeds up recovery : BPC 157 has been shown to significantly accelerate recovery from various injuries, including tendon and ligament damage
Shared decision-making remains central
These add-on costs can double or triple the monthly expense
Melanotan-2# Melanotan-2 is a cyclic heptapeptide with a lactam bridge that increases metabolic stability
Originally studied in Eastern Europe, it has been associated with the regulation of melatonin production, normalization of circadian rhythms, and activation of telomerase
